Comparing the Efficacy and Safety of Biosimilar Candidate Xlucane Versus Lucentis® in Patients With nAMD (XPLORE)
A Phase III Double-Blind, Parallel Group, Multicenter Study to Compare the Efficacy and Safety of Xlucane Versus Lucentis® in Patients With Neovascular Age-Related Macular Degeneration
Sponsor: Stada Arzneimittel AG
Listed as NCT03805100, this PHASE3 trial focuses on Macular Degeneration and remains completed. Sponsored by Stada Arzneimittel AG, it has been updated 11 times since 2019, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
11 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Dec 2023 — Jul 2024 [monthly]
Completed PHASE3
-
Apr 2022 — Dec 2023 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
▶ Show 6 earlier versions
-
Sep 2021 — Apr 2022 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Jan 2021 — Sep 2021 [monthly]
Recruiting PHASE3
-
Aug 2020 — Jan 2021 [monthly]
Recruiting PHASE3
-
Jul 2019 — Aug 2020 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Apr 2019 — Jul 2019 [monthly]
Not Yet Recruiting PHASE3
-
Feb 2019 — Apr 2019 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Stada Arzneimittel AG
- Xbrane Biopharma AB
For direct contact, visit the study record on ClinicalTrials.gov .